Search

Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023
Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
Understanding external controls and their importance to clinical trials for rare diseases